A5 Laboratories Inc. (OTC.BB:AFLB) has signed an analytical services contract with BioActif Inc. of Blainville, Quebec. Upon obtaining health Canada laboratory establishment license, A5 Labs will provide a comprehensive analytical and development services for BioActif. These services will include method development, raw materials and finished goods testing as well as stability studies.
“We are extremely pleased to have reached this agreement with such prestigious brand company such as BioActif. BioActif’s selection of our services is a terrific endorsement of our capabilities including complex analytical procedures and stability studies, and it is another significant step in establishing A5 Labs as a premium world class CRO and Biotechnology company,” said Dr. Richard Azani, President and CEO.
A5 Labs is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
A5 Laboratories Inc. has submitted a provisional patent application to protect its technology for the production of interferon-based products. In general the patent application describes the company’s new method for producing therapeutic proteins as well as specifically providing details of the production of company’s lead product VI-1718. A5 Lab’s lead product VI-1718 has potential broad based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections.
Dr. Azani said, “The submission of this patent application is a very significant milestone in the development of our interferon-based products. I am very proud of our research team for their tireless work in completing the scientific and technological basis for this patent. We are now ready to advance the company’s plans towards production and commercialization of these products.”
XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, will host a webcast conference call on Monday, August 9, 2010 at 4:30 pm Eastern time to discuss its 2010 second quarter financial results and provide a general business update.
XOMA discovers, develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government.
XOMA’s technologies have contributed to the success of marketed antibody products, including LUCENTIS� (ranibizumab injection) for wet age-related macular degeneration and CIMZIA� (certolizumab pegol) for rheumatoid arthritis and Crohn’s disease.
The company has a premier antibody discovery and development platform that incorporates an unmatched collection of antibody phage display libraries and proprietary Human Engineering(tm), affinity maturation, Bacterial Cell Expression (BCE) and manufacturing technologies. BCE is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, 60 pharmaceutical and biotechnology companies have signed BCE licenses, and several licensed product candidates are in clinical development.
Auto Search Cars, Inc. (OTCBB:ASCH) and Curaxis Pharmaceutical Corp. have completed their reverse merger with the effective date of July 29, 2010.
In connection with the Merger, Auto Search is in the process of changing its name to Curaxis Pharmaceutical Corporation. In addition Auto Search will apply to FINRA to change its trading symbol, a process which is expected to be completed in three to six weeks. As a result of the Merger, the company will concentrate exclusively on clinical development of Curaxis’ drug pipeline. In the near term, the company plans to concentrate exclusively on clinical development of its drug candidate for the treatment of Alzheimer’s disease.
In completing the merger, Auto Search issued 64.2 million shares of its common stock to the holders of Curaxis common stock. Under the terms of the Merger, all but 8.7 million of those shares will be restricted from trading for a period of one year from the closing of the Merger. After the close of the Merger a total of 71.9 million shares of common stock will be outstanding. Southridge Business Solutions Group LLC assisted with the closing of the Merger.
Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer’s disease and multiple cancers. Curaxis’ therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer’s disease and various cancers. Curaxis believes that their discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer’s patients and in multiple tumors will enable them to develop significant new treatments for Alzheimer’s disease as well as many cancers.
No comments:
Post a Comment